Intratracheal  Intravenous Liposomal Delivery of siRNA, Antisense Oligonucleotides and Anticancer Drug by unknown
Research Paper
Intratracheal Versus Intravenous Liposomal Delivery of siRNA, Antisense
Oligonucleotides and Anticancer Drug
Olga B. Garbuzenko,1 Maha Saad,1 Seema Betigeri,1 Min Zhang,1 Alexandre A. Vetcher,2,5
Viatcheslav A. Soldatenkov,3,6 David C. Reimer,4 Vitaly P. Pozharov,1 and Tamara Minko1,7
Received June 1, 2008; accepted October 10, 2008; published online October 29, 2008
Purpose. To compare systemic intravenous and local intratracheal delivery of doxorubicin (DOX),
antisense oligonucleotides (ASO) and small interfering RNA (siRNA).
Methods. “Neutral” and cationic liposomes were used to deliver DOX, ASO, and siRNA. Liposomes
were characterized by dynamic light scattering, zeta-potential, and atomic force microscopy. Cellular
internalization of DOX, ASO and siRNAwas studied by confocal microscopy on human lung carcinoma
cells. In vivo experiments were carried out on nude mice with an orthotopic model of human lung cancer.
Results. Liposomes provided for an efficient intracellular delivery of DOX, ASO, and siRNA in vitro.
Intratracheal delivery of both types of liposomes in vivo led to higher peak concentrations and much
longer retention of liposomes, DOX, ASO and siRNA in the lungs when compared with systemic
administration. It was found that local intratracheal treatment of lung cancer with liposomal DOX was
more efficient when compared with free and liposomal DOX delivered intravenously.
Conclusions. The present study outlined the clear advantages of local intratracheal delivery of liposomal
drugs for the treatment of lung cancer when compared with systemic administration of the same drug.
KEY WORDS: antisense oligonucleotides; imaging; liposomes; local lung delivery of siRNA; lung
cancer; pulmonary delivery.
INTRODUCTION
Every year, close to 400,000 Americans die of lung
disease, making it the third most frequent cause of death in
the USA (one in seven deaths). An additional 35 million
Americans are living with chronic lung diseases (1). There-
fore, the development of effective methods of drug delivery
to the lungs is an immediate and important task of modern
medicine. Traditionally, three main routes of administration
are being used to deliver therapeutic ingredients to the lungs:
oral, intravenous, and pulmonary. After oral administration,
drugs suffer from the destruction in gastro-intestinal tract and
during first-pass liver metabolism. Drugs delivered via an
intravenous route of administration accumulate not only in
the lungs but also in other organs (2,3) and may undergo
degradation in the systemic circulation. Local drug delivery to
the lung may enhance drug retention by lung cells, increase drug
concentration inside the cells, decrease the need for high drug
dose, and limit the adverse side effects of the treatment on
healthy organs. Liposomes, small lipid vesicles with a composi-
tion close to lung surfactant, have been successfully used for the
delivery of different therapeutic agents to the lung (4–11).
However, distribution of different types of liposomal carriers
and their payloads through the body after the inhalation as well
as their ability to deliver diverse active ingredients inside lung
cells have not been studied in detail. These aspects are
especially important when liposomes are used for the delivery
of potentially toxic ingredients (antibiotics, anticancer drugs,
etc.) and/or other highly effective therapeutic components
(proteins, antisense oligonucleotides, DNA, RNA, etc).
Liposomes have been widely investigated since 1970 as drug
carriers for improving the delivery of therapeutic agents to
specific sites in the body and almost immediately were explored
for cancer treatment (12,13). One of the serious obstacles
limiting therapeutic applications of liposomes is short circulation
residence time as a result of their elimination from the blood
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stream by reticuloendothelial system (RES) after systemic
administration (14,15). This problem was partially solved by
covering the liposome surface with phosphoetanolamine deriv-
atives of poly(ethylene glycol) (PEG) or other polymers. These
“neutral” and sterically stabilized liposomes (Stealth liposomes)
used as carriers for hydrophilic anticancer drugs (doxorubicin,
vincristine etc.) exhibited really long circulation time in the
vascular system (16–19) and showed enhanced accumulation of
drugs in tumor tissues (20–23).
During the past 20 years, a variety of techniques have been
developed to encapsulate and/or deliver therapeutics with
liposomes. Liposomes have been used successfully to deliver
conventional drugs or new genetic drugs including plasmid
DNA-containing therapeutic genes, antisense oligonucleotides
(ASO), and small interfering RNA (siRNA) in preclinical
models and clinical trials (24–32). The delivery of different
types of payloads in turn requires different properties of
carriers, including their surface charge. Lipophilic and hydro-
philic drugs can be incorporated into the lipid membrane or
inner aqueous space of liposomes respectively. While modified
uncharged nucleotides can be delivered by neutral or slightly
charged liposomes, native negatively charged ASO, siRNA, or
DNA molecules required cationic liposomes. The practical
application of different types of liposomes for inhalatory
delivery of various therapeutic components is limited by the
almost complete absence of data describing organ exposures by
different liposomes after their local intratracheal delivery.
In the present study, traditional “neutral” PEGylated
and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)
cationic liposomes were investigated. DOX and neutral P-
ethoxy-ASO were used as payloads for “neutral” liposomes
while DOTAP was used to deliver negatively charged siRNA.
The study was carried out to fulfill three specific aims. First,
internalization of liposomes with different sizes and charges
into lung carcinoma cells was compared in vitro. Second, two
distinct routes of administration, systemic intravenous and
local intratracheal, were compared in vivo on mice using
similar “neutral” and cationic liposomes with respective
payload. Third, the effectiveness of intravenous and intra-
tracheal treatment of lung cancer with liposomal DOX were
compared on nude mice with an orthotopic model of human
lung human A549 non-small cell lung carcinoma.
MATERIALS AND METHODS
Cell Line. A549-luc-C8 light producing cell line derived
from A549 human non-small cell lung carcinoma cells by stable
transfection of the North American Firefly Luciferase gene
expressed from the CMV promoter was obtained from Xenogen
Corporation (Alameda, California). Cells were cultured in
RPMI medium, supplemented with 10% fetal bovine serum
(Fisher Chemicals, Fairlawn, NJ). Cells were grown at 37°C in a
humidified atmosphere of 5% CO2 (v/v) in air. All experiments
were performed on cells in the exponential growth phase.
Animals. Athymic nu/nu mice 6–8 weeks old were
obtained from Taconic (Hudson, NY). All mice were main-
tained in micro-isolated cages under pathogen free conditions
in the animal maintenance facilities of Rutgers, The State
University of New Jersey.
Liposomal Compositions of Doxorubicin, Antisense Oli-
gonucleotides and siRNA. PEGylated “neutral” liposomeswere
used for delivery of electrically neutral DOX and P-ethoxy ASO.
Negatively charged siRNA was delivered by cationic DOTAP
liposomes. ASO targeted to BCL2 mRNAwere synthesized and
labeled with fluorescein isothiocyanate (FITC) by Oligos Etc.
(Wilsonville, OR) according to our design (29). The DNA
backbone of all bases in oligonucleotides was P-ethoxy modified
to eliminate an electrical charge and increase incorporation
efficacy into “neutral” liposomes. A siGLO Red transfection
indicator (RNA duplex labeled with Pierce NuLight DY-547
fluorophore) was purchased from Dharmacon Inc. (Chicago, IL)
and was used to study siRNA delivery and cellular uptake.
Doxorubicin was purchased from Sigma (St. Louis, MO).
To prepare “neutral” liposomes, lipids (Avanti Polar
Lipids, Alabaster, AL) were dissolved in chloroform, evapo-
rated to a thin film layer in a rotary evaporator, and
rehydrated with 300 mM citrate buffer, pH 4. The lipid mole
ratio for this formulation was 51:44:5 egg phosphatidylcholin/
cholesterol/1,2,-distearoyl-sn-glycero-3-phosphoethanol-
amine-N-aminopolyethelenglycol-Mw-2000 ammonium salt
respectively. ASO was loaded into liposomes by dissolving
in rehydration buffer in concentration 0.5 mM. Liposomes
were extruded gradually using polycarbonate membranes 200
and 100 nm at room temperature using an extruder device
from Northern Lipids, Inc. (Vancouver, BC, Canada). Obtained
liposomes were dialyzed overnight against 0.9% NaCl at 4°C,
and loaded with DOX (5 mg/mL) at 37°C. Liposomes were
separated from free DOX by dialysis against 100 volumes 0.9%
NaCl. The encapsulation efficacy of DOX and ASO was ∼95%
and ∼50% respectively. The final phospholipids concentration
was 10 mg/mL. Mean liposomes diameter was 100–140 nm.
Cationic liposomes were prepared from positively charged
dioleoyl-2-trimethylammonium propane-cationic (Avanti Polar
Lipids, Alabaster, AL) in concentration 5mg/mL using thin layer
procedure described above and followed by extrusion through
100 nm polycarbonate membrane. siGLO Red was dissolved in
RNAse free solution to final concentration 200 μM. DOTAP
liposomes were mixed with siGLO in ratio 6:1 v/v and incubated
at room temperature for 15 min before use. Mean DOTAP/
siGLO complexes size was >500 nm.
Aliquots of each liposomal formulation were labeled
with near infrared fluorescent dye Cy5.5 Mono NHS Ester
(GE Healthcare, Amersham, UK) or fluorescein isothiocya-
nate FITC. A fluorescent dye was dissolved together with
lipids in chlorophorm. Approximate excitation/emission
maxima of all used fluorescent substances are: 675 nm/
694 nm (Cy5.5); 557 nm/570 nm (siGLO Red, siRNA
labeled with DY-547 dye); 494 nm/518 nm (FITC); 470 nm/
585 nm (DOX).
Liposome Size and Zeta Potential. Particle size was
measured by dynamic light scattering using 90 Plus Particle
Sizer Analyzer (Brookhaven Instruments Corp., New York,
NY). Aliquot of 40 μL of each sample was diluted in 2 mL of
its external buffer. Zeta potential was measured on PALS
Zeta Potential Analyzer (Brookhaven Instruments Corp,
New York, NY). Samples were taken as is and their volume
was 1.5 mL. All measurements were carried out at room
temperature. Each parameter was measured in triplicate, and
average values were calculated.
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Atomic Force Microscopy. The shape of cationic, “neu-
tral” conventional and PEGylated liposomes were studied by
atomic force microscopy (AFM) imaging using the previously
described procedure (33). Briefly, 50 μL of liposome suspen-
sion in water was deposited on pre-cut (∼25×25 mm2) and
pre-cleaned Plain Premium microscope slides (Fisher Scientific
Co, Pittsburgh, PA), kept for 10 min at 100% humidity to
achieve particles precipitation. Water was removed by dry
nitrogen flow and dried samples were subjected to imaging with
an atomic force microscope (Nano-R AFM Pacific
Nanotechnology Instrument, PNI, Santa Clara, CA) in close
contact (tapping) mode using tapping mode etched OMCL-
AC160TS silicon probes (Olympus Optical Co. Tokyo, Japan).
The captioning was performed in the height mode. The images
were processed, and the measurements were performed with
Femtoscan software v. 2.2.85(5.1) (Advanced Technologies
Center, Moscow, Russia). For statistics, no less than 50 objects
of each sample were analyzed.
Confocal Microscopy. Cellular internalization of lipo-
somes, DOX, ASO and siRNA were monitored in A549 lung
cancer cells by confocal microscopy. Three series of the experi-
ments were carried out: (1) FITC-labeled “neutral” liposomes
(green fluorescence) containedDOX (intrinsic red fluorescence);
(2) “neutral” liposomes labeled with Cy5.5 (red fluorescence)
contained ASO labeled with FITC (green fluorescence); (3)
FITC-labeled cationic liposomes (green fluorescence) contained
siGLO Red (red fluorescence). Cells were separately incubated
24 h at 37°C with each liposomal formulation. Red and green
fluorescence images were photographed and digitally overlaid.
Superimposition of images allows for detecting of co-localization
of labeled liposomes and their payload (yellow color).
Content of Liposomes in Different Organs. The distribu-
tion of different liposomes and their payload was examined
on nude mice. Labeled, empty “neutral” and cationic lip-
osomes as well as different liposomes containing DOX,
labeled ASO or siRNA were delivered by intratracheal or
intravenous administrations. Injected volume of liposomes
was 100 μL for each formulation; DOX concentration was
2 mg/kg. Animals were anesthetized with isoflurane and
euthanized 30 min, 1 h, and 24 h after the treatment. Lungs,
heart, liver, spleen, and kidneys were excised, rinsed in saline,
and fluorescence was registered by IVIS imaging system
(Xenogen Corporation, Alameda, CA). Visible light and
fluorescence images were taken and overlaid. The intensity
of fluorescence was represented on composite light/fluores-
cent images by different colors with blue color reflecting the
lowest fluorescence intensity and red color—the highest
intensity. Images of each organ were then scanned and total
fluorescence intensity was calculated by a special computer
program originally developed for our laboratory by Dr. V. P.
Pozharov. Preliminary experiments showed a strong linear
correlation between the total amount of labeled substance
accumulated in the organ and calculated total fluorescence
intensity (data are not shown). The fluorescence was
expressed in arbitrary units with 1 units represented approx-
imately 2×1010 photons/s/sr/cm2. The method allows a
quantitative comparison of the concentration of the same
fluorescent dye between different series of the experiments.
The mass of all organs was measured. No statistical
differences were found in the mass of each organ between
all experimental groups of animals. The fluorescence intensity
was normalized for organ weight. In an additional series of
the experiments, fluorescence of labeled “neutral” and
cationic liposomes in lungs was analyzed 30 min, 1 h, 1 day,
3 days, 5 days, 8 days, and 10 days after the administration.
The concentration of liposomes in the lungs was plotted
versus the time, and area under the curve (AUC) reflecting a
total lung tissue exposure was calculated.
Orthotopic Mouse Model of Human Lung Cancer and
Tumor Treatment. Orthotopic engraftment of tumor was estab-
lished by intratracheal (i.t.) instillation of 5.0×106 A549 human
non-small cell lung carcinoma cells into athymic nu/nu mice.
Tumor growth was monitored once a week by real-time
bioluminescence in vivo with an imaging system using luciferase
expressing lung cancer cells (Xenogen Bioscience, Cranbury,
NJ). To compare the anticancer effectiveness of local
(intratracheal) and systemic (intravenous) administration of
liposomal drugs, the following experiments have been
performed. After the instillation of cancer cells, tumor growth
was monitored for 6 weeks and mice were randomized into four
groups (five animals per group) based on tumor burden as
measured by in vivo imaging. The animals from the first group
were not treated (untreated tumor control). Group 2 received a
single dose of doxorubicin (2 mg/kg) via intravenous injection in
phosphate buffered saline. Groups 3 and 4 received the
liposomal formulation of doxorubicin (2 mg/kg) via intravenous
injection and intratracheal instillation, respectively. The dose of
2 mg/kg was estimated in preliminary experiments as a maximum
tolerated dose for liposomal DOX. Twenty-four hours after the
treatment, animals from all groups were sacrificed, and lung
tissue samples from each animal were fixed in 10% buffered
formalin. Each tissue sample was trimmed, embedded in
paraffin, sectioned and stained with hematoxylin and eosin for
histopathological evaluation. The evaluation was performed by a
veterinary pathologist. Ten slices per each sample were evaluated
under the same magnification. The number of cancer cells in
each microscopic field of view was calculated and presented as
percent of untreated tumor control (group # 2).
Endotracheal Instillation of Lung Cancer Cells and Lip-
osomes. Mice were anesthetized through intraperitoneal injec-
tion with 80 mg/kg ketamine and 10–12 mg/kg xylazine. Once
anesthetized, the mouse was placed on the titling rodent work
stand (Hallowell EMC, Pittsfield, MA) in supine position and
restrained in position by an incisor loop. The tongue was then
extruded using atraumatic forceps or via rotation with a cotton
tip applicator. The larynx was visualized using a modified 4 mm
ear speculum attached to an operating head of an ophthalmo-
scope (Welch Allyn, Skaneateles Falls, NY). The modified
speculum, acting as a laryngoscope blade, in an inverted
fashion provided dorsal displacement of the tongue and
magnification of the laryngeal opening. One hundred micro-
liters of cells or liposomes in suspension were instilled within
the trachea using a 40 mm length of Clay Adams Intramedic
polyethylene tubing (Diagnostic Systems, Sparks, MD, PE-10,
I.D 0.28 mm, O.D. 0.61 mm), attached to a 27 gauge
hypodermic needle. The tubing was advanced approximately
10 mm past the epiglottis. The tubing and speculum were
withdrawn immediately after instillation. The mouse was then
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removed from the work stand and held in a vertical position by
the scruff until multiple normal respirations were observed.
Statistical Analysis. Data were analyzed using descriptive
statistics, single-factor analysis of variance (ANOVA), and
presented as mean values ± the standard deviation from four
to eight independent measurements. The comparison among
groups was performed by the independent sample Student’s t-
tests. The difference between variants is considered signifi-
cant if P<0.05.
RESULTS
Particle Size and Zeta Potential Measurements. Table I
shows the size and zeta potential of liposomal compositions
used in the study. As can be seen, “neutral” liposomes have a
slight negative charge. The finding that the zeta potential of
lipid assemblies containing PEG-DSPE is negative is in
agreement with our previously reported data (31). It also
supports the “hidden charge effect” that was suggested for
liposomes sterically stabilized through grafting of mPEG-
DSPE with PEG moiety ≥0.75 kDa (34,35). Similar to their
conventional counterpart, these liposomes can be considered
“neutral.” Inclusion of DOX and ASO into “neutral” lip-
osomes did not change their size and zeta potential. The
diameter of positively charged DOTAP liposomes after
extrusion was about 100–140 nm (same as for “neutral”
liposomes). Mixing with siRNA in ratio 6:1 v/v lipid/siRNA
respectively led to formation of rather large DOTAP/siRNA
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Fig. 1. Assessment of different liposomes by atomic force microsco-
py. Typical images of neutral conventional and “neutral” liposomes,
cationic liposomes, and complexes of cationic liposomes with siRNA
are shown. Liposome suspensions were applied on freshly cleaved
mica, kept for 10 min at 100% humidity atmosphere to achieve
deposition, and dried under nitrogen flow to remove external water.










Fig. 2. Intracellular localization of different liposomes and their
payload. A-549 lung cancer cells were incubated with substances
indicated and visible light and fluorescent images (red and green
fluorescence) were taken by a confocal microscope. Visible light
image was digitally overlaid with both fluorescence images to obtain a
composite image showing co-localization of liposomes and their
payload (in yellow color). The upper panel contains representative
images of “neutral” liposomes labeled with FITC (green fluores-
cence) containing Doxorubicin (DOX, intrinsic red fluorescence).
The middle panel shows representative images of complexes of
“neutral” liposomes labeled with near infrared dye Cy5.5 (red
fluorescence) containing FITC labeled antisense oligonucleotides
(ASO, green fluorescence). The bottom panel contains representative
images of complexes of FITC labeled cationic liposomes (green
fluorescence) with siRNA labeled with DY-547 dye (red fluores-
cence). Superimposition of images allows for detecting of co-
localization of liposomes and their payload inside cells (yellow color).
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complexes and decreased surface charge likely due to the
electrostatic interactions between positively charged lipid and
negatively charged siRNA.
Atomic Force Microscopy. Atomic force microscopy
(AFM) was widely used during the last decade to characterize
morphology of nanoparticles. AFM topographical images of
the liposome preparations revealed convex meniscus shaped
particles that were uniformly distributed on the mica surface
(Fig. 1). No substantial presence of liposome aggregates were
observed as expected from physico-chemical properties of
uniformly charged particles. Since liposomes flatten on the
mica surface after deposition and drying process results in
distortion of their actual shape in suspension, we calculated
the value of reconstructed diameter (d) from the liposomes
volume measured by AFM (V) under the assumption that
liposomes adopt the spherical shape in aqueous solutions,
using the equation d ¼ 6V=ð Þ1=3 as previously described
(31). The complexation of liposomes with siRNA resulted in
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Fig. 3. Organ content of “neutral” liposomes. PEGylated liposomes were labeled with near infrared Cy5.5
dye and delivered intravenously or intratracheally into the mice. The distribution of liposomes was measured
using the IVIS Xenogen imaging system. The upper panel (a) contains representative images of different
organs excised 0.5, 1 and 24 h after injection. The intensity of fluorescence is expressed by different colors
with blue color reflecting the lowest intensity and red color—highest intensity. The bottom panel (b)
demonstrates average total content per an entire organ and concentration (per gram of organ weight) of
labeled liposomes. Means ± SD are shown.
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Furthermore, liposomes modification with siRNA makes
their appearance “fuzzy”, thus hiding object topology.
Cellular Uptake of Liposomes, ASO, DOX, and
siRNA. The delivery of ASO, DOX and siRNA by lip-
osomes into cells was studied in vitro using confocal
microscopy. A-549 human lung carcinoma cells were incu-
bated with “neutral” liposomes containing ASO or DOX,
cationic liposomes labeled with Cy5.5 or DOTAP/siRNA
complexes and then intracellular liposomes distribution was
examined. Results are shown on Fig. 2. As can be seen, after
24 h incubation, “neutral” and cationic liposomes were
detected in the cellular cytoplasm and nucleus. Fluorescence
of the payload of “neutral” liposomes (DOX or ASO) was
also registered both in the cellular cytoplasm and nucleus. It
is known that liposomes quench the fluorescence of any
loaded agent (36). Therefore, the visualization of fluores-
cence strongly suggests that after 24 h of incubation ASO
and DOX were completely released from liposomes and
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Fig. 4. Organ content of cationic liposomes. Liposomes were labeled with near infrared dye Cy5.5 and
injected intravenously or intratracheally into the mice. The distribution of liposomes was measured using
IVIS Xenogen imaging system. The upper panel (a) contains representative images of different organs
excised 0.5, 1 and 24 h after injection. The intensity of fluorescence is expressed by different colors with blue
color reflecting the lowest intensity and red color—highest intensity. The bottom panel (b) demonstrates
average total content per an entire organ and concentration (per gram of organ weight) of labeled liposomes.
Means ± SD are shown.
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obtained also show that after 24 h of incubation, a
substantial amount of complexes DOTAP/siRNA penetrat-
ed into cellular cytoplasm area (Fig. 2, bottom panel)
despite their relatively big size (>500 nm). In order to prove
that liposomes were not adhered on the cell surface but
actually penetrated the cells, we analyzed their distribution
in different cellular layers from the upper to the lower of the
fixed cells (z-sections, results are not presented). The data
obtained show that the distribution of either small (100–
140 nm) “neutral” and cationic liposomes or large
(>500 nm) DOTAP/siRNA complexes in cytoplasm and
nucleus was very similar in different cell layers. Therefore,
both systems can be used for delivery of therapeutic agents
with biological activity into the cellular cytoplasm and
nuclei.
Organ Content of “Neutral” and Cationic Liposomes
After Intravenous and Intratracheal Instillation. Analysis of
the total organ content of “neutral” and cationic liposomes
revealed several common and distinct features (Figs. 3, 4,
and 5). After intravenous (i.v.) injection the total content of
both types of liposomes per an entire organ was highest in
liver, kidneys, and lungs. However, the total amount of
“neutral” liposomes retained in these organs was higher
when compared with cationic liposomes. Intratracheal instil-
lation (i.t.) of both types of liposomes substantially increased
their total amount in entire lungs and decreased the content
in other organs. Twenty four hours after i.t. injection, a
substantially higher amount of labeled “neutral” liposomes
per an entire organ was found in the lungs when compared
with cationic liposomes. In addition, total content of lip-
osomes in organs was normalized for organ weight. The
concentrations of liposomes were highest in the kidneys and
the lungs after intravenous injection. Intratracheal adminis-
tration of liposomes limited the exposure of the kidneys and











































































































































Fig. 5. Retention of different liposomes in lung tissues after intravenous (i.v.) and intratracheal (i.t.) instillation. The
fluorescence of neutral PEGylated and cationic liposomes labeled with Cy5.5 was measured in the excised lungs within
10 days. An absolute and normalized per organ weight levels of fluorescence were plotted versus time and an area under the
curve (AUC) was calculated. Means ± SD are shown. *P<0.05 when compared with intravenous injection.
388 Garbuzenko et al.
tracheal delivery of liposomes led to their much higher
concentration in the lungs and retained this higher concen-
tration for a much longer period of time when compared with
intravenous injection (Fig. 5). It was found that liposomes
completely eliminated from the lungs on the second–third
days after intravenous injection. In contrast, a substantial
concentration of liposomes was observed in the lungs during
this period. The overall lung exposure calculated as an area
under the curve (AUC) was 4 to 7.5 times higher after
intratracheal instillation when compared with the intravenous
injection. Therefore, intratracheal delivery of liposomes
substantially increased the overall tissue exposure in the
lungs and reduced the exposure and the peak tissue liposomal
concentrations in other organs.
Organ Content of Free and Liposomal DOX. During the
first 0.5 h after i.v. injection, a comparable total amount of
DOX was found in all investigated organs (Fig. 6). However,
at the later time-periods, the distribution was substantially
changed. The highest total amount of DOX per an entire
organ was found in the liver and kidneys, while the
concentration of DOX was highest in the kidneys. Only
trace amounts of DOX were found in the lungs 24 h after i.v.
injection. Delivery of DOX by “neutral” liposomes substan-
tially increased its total amount and concentrations in all
studied organs (Figs. 7 and 8). However, the tendency in the
dynamic of the organ concentration of DOX delivered by
liposomes was similar to that of free DOX. During the first
hour after its i.v. systemic delivery by liposomes, DOX was
found predominately in the liver, kidneys, and lungs, and
DOX concentration per gram of tissue was highest in the
lungs and kidneys. The amount of DOX in the lungs
declined 24 h after treatment. Intratracheal local delivery
of liposomal DOX substantially changed the distribution of
delivered DOX between the studied organs. After i.t.
delivery, a predominant amount of the drug was found in
the lungs during all studied time periods after injection. The
analysis of accumulation of DOX normalized for organ
weights showed that the tissue concentration of the cytotoxic
drug in the lungs was elevated for a prolonged period of
time and the peak tissue levels in the non-targeted tissues
were reduced after intratracheal local delivery of liposomal
DOX.
Organ Content of ASO and siRNA Delivered by “Neu-
tral” and Cationic Liposomes After Intravenous and Intra-
tracheal Injection. Organ content of ASO and siRNA
delivered by “neutral” and cationic liposomes was similar to
that of liposomal DOX (please compare Figs. 7, 8, and 9).
Intravenous delivery led to the highest total content per an
entire organ of ASO and siRNA in the liver, kidneys, and
lungs. In most cases, 24 h after the i.v. injection the liposomal
payloads were found mainly in the liver and kidney, while
their amount retained in the lungs substantially decreased
when compared with earlier periods after the treatment. It is
interesting, that an amount of relatively large DOTAP/siRNA
complexes (>500 nm) accumulated in the lungs was higher in
the later stages of the experiment (1–24 h), while the quantity
of smaller cationic liposomes without siRNA (100–140 nm)
was higher in the earlier stages (0.5–1 h). It is possible that
larger liposome/siRNA complexes require longer time for the
degradation of an entire complex and siRNA release. Similar
to liposomal DOX, after i.t. delivery, the highest concen-
trations of siRNA and ASO in all investigated time-points
were registered in the lungs, while concentrations in non-




































































Fig. 6. Organ content of free doxorubicin (DOX). DOX was injected
intravenously into the mice. The distribution of DOX possessing
intrinsic fluorescence was measured using the IVIS Xenogen imaging
system. The upper panel (a) contains representative images of
different organs excised 0.5, 1 and 24 h after injection. The intensity
of fluorescence is expressed by different colors with blue color
reflecting the lowest intensity and red—highest intensity. The bottom
panel (b) demonstrates average total content per an entire organ and
concentration (per gram of organ weight) of DOX. Means ± SD are
shown.
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after i.v. injection, the highest concentrations of ASO as
siRNA were found in the kidneys.
Intratracheal and Intravenous Treatment of Lung Tu-
mor. Human lung tumor-bearing mice were injected with
free DOX and liposomal DOX intravenously and intra-
tracheally respectively. The results of these experiments are
shown on the Fig. 10. It was found that treatment with
intravenous injection of free DOX slightly decreased the
number of cancer cells in the lungs (bar 2). Intravenous
treatment with liposomal DOX led to a more substantial
decrease in the number of tumor cells (bar 3). However, the
most significant positive effect was found after the local
delivery of liposomal DOX directly to the lungs by intra-
tracheal injection (bar 4). In this case, after local intra-
tracheal delivery of liposomal DOX, the number of cancer
cells was decreased by 45% when compared with untreated
tumor, by 38% when compared with treatment by intrave-
nous injection of free DOX, and by 30% when compared
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Fig. 7. Organ content of “neutral” liposomes containing doxorubicin (DOX). PEGylated liposomes were
delivered intravenously or intratracheally into the mice. Intrinsic fluorescence of DOX was measured using
IVIS Xenogen imaging system. The upper panel (a) contains representative images of different organs
excised 0.5, 1 and 24 h after injection. The intensity of fluorescence is expressed by different colors with blue
color reflecting the lowest intensity and the red color reflecting the highest intensity. The bottom panel (b)
demonstrates average total content per an entire organ and concentration (per gram of organ weight) of
labeled liposomes. Means ± SD are shown.
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DISCUSSION
It is well known that liposomal drug formulations are
more efficient in terms of their cellular internalization,
specific activity, and adverse side effects when compared
with free drugs (28,37–43). Liposomes of different sizes and
surface electric charges are currently being used for the
delivery of encapsulated drugs or complexated large mole-
cules. In addition to systemic intravenous injection, different
routes of liposome administration including pulmonary have
been proposed. While the high effectiveness of liposomal
formulations is widely acknowledged, several aspects of
liposomal drug delivery are not clearly understood. It is not
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Fig. 8. Organ content of antisense oligonucleotides (ASO) delivered by “neutral” liposomes. P-ethoxy
neutral ASO were labeled with fluorescein isothiocyanate (FITC), encapsulated into “neutral” liposomes
and delivered intravenously or intratracheally into the mice. The distribution of ASO was measured using
the IVIS Xenogen imaging system. The upper panel (a) contains representative images of different organs
excised 0.5, 1 and 24 h after injection. The intensity of fluorescence is expressed by different colors with blue
color reflecting the lowest intensity and red color reflecting the highest intensity. The bottom panel (b)
demonstrates average total content per an entire organ and concentration (per gram of organ weight) of
labeled ASO. Means ± SD are shown.
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liposomal drugs in terms of their successful intracellular
uptake, organ retention, and treatment efficacy after admin-
istration via different routes. We address the problem in the
present study by investigating in vitro cellular uptake and
intracellular localization along with in vivo organ exposure
after intravenous or intratracheal administration of small
slightly negative (“neutral”) and positively charged lip-
osomes as well as their relatively large complexes with
siRNA.
We used small “neutral” PEGylated and positively
charged DOTAP liposomes. DOX and uncharged P-ethoxy
ASO were used as a payload for neutral liposomes while
siRNA was complexated to cationic liposomes. Atomic force
microscopy and light scattering data showed that empty
liposomes of both types represent homogenous spherical
structures with diameter of 100–140 nm. Loading of “neutral”
liposomes with DOX or neutral modified ASO did not
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Fig. 9. Organ content of siRNA delivered by cationic liposomes. siRNA labeled with near infrared dye
(siGLO red) was complexated with cationic liposomes and delivered intravenously or intratracheally into the
mice. The distribution of siRNA was measured using IVIS Xenogen imaging system. The upper panel (a)
contains representative images of different organs excised 0.5, 1 and 24 h after injection. The intensity of
fluorescence is expressed by different colors with blue color reflecting the lowest intensity and red color
reflecting the highest intensity. The bottom panel (b) demonstrates average total content per an entire organ
and concentration (per gram of organ weight) of labeled siRNA. Means ± SD are shown.
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complexation of cationic liposomes with siRNA led to
dramatic (up to ten-times) increase in their diameter.
Investigation of cellular internalization, localization, and
distribution of liposomes showed that despite the differences
in size, both small empty and loaded liposomes as well as
relatively large complexes were able to deliver their payload
to the cellular cytoplasm and even nuclei. Moreover, labeled
“neutral” liposomes, as well as their payload, were found
inside cellular nuclei. These data confirm our previous
transmission electron and fluorescence microscopy findings
for the nuclear penetration of conventional and “neutral”
liposomes with average size of 100–200 nm both in vitro and
in vivo (28,31,44). It seems that, in contrast to small lip-
osomes, relatively large DOTAP/siRNA complexes were not
able to penetrate cellular nuclei. Therefore, liposomes and
liposomal complexes of different sizes (100–1000 nm) used in
this study were able to provide an efficient delivery of
different biologically active substances, including antibiotics,
antisense oligonucleotides, and small interfering RNA into
the cellular cytoplasm.
Systemic administration of drugs, especially for treat-
ment of lung diseases has several disadvantages including, but
not limited to, unfavorable organ accumulation and decrease
in specific drug activity as a result of drug deactivation during
systemic circulation and high possibility of adverse side
effects on healthy organs. Delivery of biologically active
substances as liposomal prodrugs can partially improve the
situation especially in case of using “neutral” “stealth”
liposomes as carriers. However, our data showed that intra-
tracheal administration of liposomes sustained higher con-
centrations of liposomes for up to three days and their
payload in the lungs for at least 24 h after instillation. Once
again, the size of liposomes and liposomal complexes with
siRNA played a secondary role, while the route of adminis-
tration served as the primary determinant of organ exposure
by liposomes and their payload. Therefore, after the intra-
tracheal delivery the tissue concentrations of liposomes and
their payload in the lungs were elevated for a prolonged
period of time and the peak tissue levels in the non-target
tissues were reduced. These data clearly show potential
advantages of local lung delivery of different liposomal
therapeutics for the treatment of lung diseases and confirm
that liposomes can be used for intratracheal delivery of drugs,
antisense oligonucleotides, and siRNA into the lungs.
The efficient delivery of therapeutics to the site of action,
however, does not automatically guarantee successful treat-
ment of a disease. In order to confirm that intratracheal
delivery of anticancer drugs can enhance the effectiveness of
treatment of lung diseases, we used the orthotopic mice
model of human lung cancer. Mice bearing human cancer
cells in their lungs were treated with free and liposomal
doxorubicin delivered intravenously and intratracheally. It
was found that intratracheal treatment was much more
efficient in limiting the growth of lung cancer cells in the
lungs when compared with free and liposomal DOX deliv-
ered via the systemic route. Therefore, the present study
showed advantages of local intratracheal delivery of liposo-
mal drugs for the treatment of lung cancer when compared
with systemic administration of the same drug.
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